Annals of Disaster Medicine
| ISSN:1684-193X
|
Updated
Dec 18 , 2005 |
|
Contents:
Volume 4, Supplement 1; October, 2005 |
|
Organophosphate Intoxication
|
Vei-Ken Seow, MD; Tzong-Luen Wang, MD, PhD |
From the Department of Emergency Medicine (Seow VK, Wang TL), Shin-Kong Wu Ho-Su Memorial Hospital,
Taiwan
Correspondence to Dr. Tzong-Luen Wang, Department of Emergency Medicine, 95 Wen Chang Road, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan . E-mail M002183@ms.skh.org.tw
|
Abstract |
|
|
Organophosphate compounds are potent inhibitors of cholinesterase; most of these compounds are used as insecticides, pesticides, or drugs. Like many other countries, poisoning with organophosphate compounds is one of the most important causes of intoxication in Taiwan. Manifestations depend on the agent and its concentration. The mode of contact in organophosphate poisoning varies, as these compounds are absorbed efficiently by oral, dermal, conjunctival, gastrointestinal, and respiratory routes. Organophosphates strongly inhibit both true acetylcholinesterase and pseudocholinesterase which leads to accumulation of acetylcholine at the synapses. As a result, muscarinic and nicotinic symptoms appear. The onset of the signs and symptoms of organophosphate poisoning varies with the route and degree of exposure. Treatment of poisoning with organophosphate is directed toward four goals: (1) decontamination, (2) supportive care, (3) reversal of acethylcholine excess at muscarinic sites, and (4) reversal of toxin binding at active sites on the cholinesterase molecule. Due to potential prolonged effects of acetylcholinesterase inhibition, most individuals with significant exposures require hospital admission and regular follow up.
Key words--- Organophosphate; Antidote; Toxicology; Cholinesterase
|
|
Introduction
|
|
|
|
Organophosphates (OP) are used widely in agriculture, horticulture, and veterinary medicine. These insecticides also are used domestically and in public hygiene to control vectors of disease. Some OP compounds (e.g., malathion) are used to treat human infestation with scabies, head lice, and crab lice. Examples of OPs include insecticides (malathion, parathion, diazinon, fenthion, chlorpyrifos), nerve gases (soman, sarin, tabun, VX), ophthalmic agents (echothiophate, isoflurophate), and antihelmintics (trichlorfon).1 The primary action of OP insecticides on insects, and the source of their potential toxicity to humans, is a consequence of their ability to inhibit the enzyme acetylcholinesterase (AChE).2,3 The result is an acetylcholine (ACh) excess syndrome.
|
|
|
Pathophysiology of Toxic Effects |
|
|
Pathophysiology of Toxic Effects
(CNS). The primary mechanism of action of OP
is inhibition of acetylcholinesterase (AChE). Acetylcholinesterase (true or red blood cell
acetylcholinesterase) is a neurotransmitter found
primarily in erythrocyte membranes, nervous tissue, and skeletal muscle.Plasma
cholinesterase(pseudocholinesterase, butyrylcholinesterase) is found in the serum,
liver, pancreas, heart, and brain. Its normal physiologic action is to break down
acetylcholine (ACh). OP inactivates AChE by
phosphorylating the serine hydroxyl group located at the
active site of ACh. Inhibition of cholinesterase leads to acetylcholine accumulation at nerve
synapses and neuromuscular junctions, resulting in overstimulation of acetylcholine receptors,
including muscarinic and nicotinic receptors. This initial overstimulation is followed by
paralysis of cholinergic synaptic transmission in the
CNS, in autonomic ganglia, at parasympathetic and sympathetic ganglionic nicotinic sites,
postganglionic cholinergic sympathetic and
parasympathetic muscarinic sites and skeletal muscle
nicotinic sites.4,5 Once an OP binds to AChE, the enzymes can undergo 3 processes, including (1)
endogenous hydrolysis of the phosphorylated enzyme
by esterases or paraoxonases, (2) reactivation by nucleophile such as pralidoxime (2-PAM),
and (3) biological changes that render the phosphorylated enzyme inactive
(aged).7 Aging is a term describing the permanent, irreversible
binding of the organophosphorous compound to the cholinesterase. The time to aging is slightly
variable with different agents. It can take minutes
to a day or more. Once aging occurs, the enzymatic activity of cholinesterase is permanently
destroyed, and new enzyme must be resynthesized over a period of weeks before clinical
symptoms resolve and normal enzymatic function returns. Therapeutic agents must be given
before aging occurs to be effective. |
|
|
The Route of OP Poisoning |
|
|
Toxicity may occur after inhalation, after ingestion, or through skin contamination. Although dermal absorption of OP compounds tends to be slow, severe poisoning still may ensue if exposure is prolonged. Skin contact and subsequent absorption is the major route of exposure occupationally. Inhalation of OP insecticides, particularly during the manufacture of formulations (e.g., because of inefficient operating ventilation equipment) or during spraying or mixing, is a recognized occupational hazard. Ingestion is uncommon in the workplace but can occur accidentally in workers with poor personal hygiene, such as those who do no remove contaminated clothing or fail to wash their hands. This exposure is likely to lead to only mild features, whereas the deliberate ingestion of an OP insecticide is likely to result in more severe features of intoxication. Massive OP intoxication can occur during suicidal and accidental events such as terrorist action in Tokyo subway in 1995.
|
|
|
Clinical Presentation |
|
Clinical presentations depend on the specific agent involved, the quantity absorbed, and the type of exposure. Most acutely poisoned patients are symptomatic within the first 8 hours and nearly all within the first 24 hours. However, highly fat-soluble compounds may cause recurrent or delayed symptoms and signs on redistribution from adipose tissue. Signs and symptoms of OP poisoning can be divided into 3 broad categories, including (1) muscarinic
effects, (2) nicotinic effects, and (3) CNS effects. Muscarinic effects can be remembered
by a mnemonic device, SLUDGE (salivation, lacrimation, urinary incontinence, diarrhea,
gastrointestinal upset and emesis) and DUMBELS (defecation, urination, miosis, bradycardia,
bronchorrhea, bronchospasm, emesis, lacrimation and salivation). Nicotinic stimulation at
neuromuscular junctions results in muscle fasciculations, cramps, and muscle weakness.
This syndrome may progress to diaphragmatic failure, paralysis and areflexia. Respiratory
muscle paralysis results in acute respiratory
failure and death. Miosis and muscle fasciculations
are considered reliable signs of toxicity. CNS effects include anxiety, restlessness, confusion,
ataxia, emotional lability, headache, dizziness, delirium, hallucination, seizures, insomnia,
tremors and coma.8 |
|
|
Intermediate Syndrome (IMS) |
|
An intermediate syndrome may occur 24~96 hours after resolution of an acute organophosphate poisoning. It may manifest as paralysis and respiratory distress syndrome involves neck flexor muscles, proximal muscle groups, respiratory muscles and muscles innervated by the cranial nerves, with relative sparing of distal muscle. It may be prevented by aggressive early antidote therapy. It may resolve within 4~18 days. 6 |
|
|
Organophosphate-induced Delayed Polyneuropathy (OPIDP) |
|
|
Organophosphate-induced delayed polyneuropathy occurs 2 weeks after exposure to large doses of certain OPs. Unlike intermediate syndrome, it may involve distal muscle with relative sparing of the neck muscles, cranial nerves, and proximal muscle groups. 12,13,14,16 |
|
|
Diagnosis |
|
|
The diagnosis of organophosphate poisoning is often difficult. Suspicion of OP poisoning is
based on history, the presence of a suggestive toxidrome and maybe noting a characteristic
hydrocarbon or garlic-like odor. It may be confirmed by demonstrating reduced levels of
cholinesterase activity in plasma and erythrocytes.
Unfortunately, many hospital laboratories do not have the in-house capability to determine
cholinesterase levels. RBC AChE represents the AChE found in CNS gray matter, RBCs and
brain. Plasma AChE is a liver acute phase protein that circulates in the blood, white matter,
the pancreas and the heart. In acute exposures, the plasma cholinesterase levels fall first, with
decreases in RBC cholinesterase levels lagging behind. Patients with chronic exposures may
demonstrate only reduced RBC cholinesterase activity, and their plasma cholinesterase may
show false-negative result, with symptomatic patients having determinations in the normal
range. Plasma cholinesterase levels have little prognostic value in patients with OP poisoning.
Its level does not correlate with severity. Other laboratory findings are nondiagnostic but may be used as reference
such as leukocytosis with a normal differential, anion gap acidosis, evidence of pancreatitis,
hypo- or hyperglycemia and liver function abnormalities. ECG findings can be prolonged
QTc interval, elevated ST segment and prolonged PR
interval. 9
|
|
|
Management |
|
|
Management of poisoning with OP is directed toward four goals: (1) decontamination, (2) supportive care, (3) reversal of acethylcholine
excess at muscarinic sites, and (4) reversal of toxin
binding at active sites on the cholinesterase
molecule. 10,11
Decontamination is very important in cases of dermal exposure since its absorption is rapid.
These should include: rapid identification of the offending agent and swift decontamination by
well-protected emergency medical personnel. Universal precautions including eyeshields,
protective clothing, and nitrile or butyl rubber gloves
instead of latex must be worn to prevent secondary contamination of health care workers.
In the case of ingestion, standard GI
decontamination procedures are of questionable benefit
because of the rapid absorption of these compounds.
Since most of the morbidity and mortality primarily results from airway and respiratory
failure, airway protective and management should be put on the first priority. Supportive
care should be directed to suctioning of secretions and vomitus, 100 percent oxygenation, a
cardiac monitor, pulse oximeter, and when necessary, ventilatory support. A
nondepolarizing agent for rapid sequence intubation should be used when neuromuscular
blockade is needed. Succinylcholine is metabolized by plasma cholinesterase, and therefore,
prolonged paralysis may result. Monitor neck muscle weakness and mental status regularly to
assess progression or decompensation.
The mainstay of medical therapy in OP poisoning is atropine or glycopyrrolate and
2-PAM (pralidoxime). Atropine, a competitive antagonist of acetylcholine at CNS and
peripheral muscarinic receptors, is used to reverse
muscarinic and central effects secondary to excessive parasympathetic stimulation. Large
doses of atropine may be required, and the usual
regimen is 2 to 5 mg intravenously every 5 minutes until control of mucous membrane
hypersecretion is attained and the airway cleared.
Mydriasis and marked tachycardia are the early signs of atropinization. The end-point of
atropinization is drying of respiratory secretions.
Atropine should not be withheld in the face of a tachycardia that may be the result of hypoxia
due to secretions, respiratory muscle paralysis, or ganglionic stimulation. Atropine does not
reverse muscle weakness. 18
Pralidoxime (2-PAM, Protopam) is a nucleophilic agent that reactivates the
phosphorylated AChE by binding to the OP molecule.
It breaks up the organophosphate-acetylcholinesterase complex and restores
acetylcholinesterase activity at both muscarinic and nicotinic
sites. The medication may be given in a bolus of 1 to 2 g intravenously over 30 ~ 60 minutes
every 4 to 8 hours. It is commonly stated that pralidoxime is useful only within the first 24 hours
after poisoning because of aging of the organophosphate-acetylcholinesterase complex.
Pralidoxime is not administered to asymptomatic patients or to patients with known
carbamate exposures presenting with minimal symptoms. |
|
|
Conclusion |
|
|
|
Organophosphate is a chemical compound that brings hazardous effects to people. Thus, prevention of getting exposure and professional management of intoxication by emergency staff should be emphasized. Due to potential prolonged effects of acetylcholinesterase inhibition, most individuals with significant exposures require hospital admission and regular follow up. |
|
|
|
|
|
References |
|
|
|
1. |
Himuro K, Murayama S, Nishiyama K: Distal sensory axonopathy after sarin
intoxication. Neurology. 1998;51:1195-7. |
2. |
Feldman RG. Organophosphates. Occupational and Environmental
Neurotoxicology 1998; Lippincott-Raven. |
3. |
Davies JE. Changing profile of pesticide poisoning. N Engl J Med. 1987;316:807-8. |
4. |
Kamanyire R, Karalliedde L. Organophosphate toxicity and occupational exposure.
Occupational Medicine (Oxford). 2004;54:69-75. |
5. |
Maddy KT, Edminston S, Richmond R. Illness, injuries, and deaths from pesticide
exposures in California 1949-1988. Rev Environ Contam Toxicol.
1990;114:58-123. |
6. |
Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides.
An intermediate syndrome. N Engl J Med. 1987;316:761-3. |
7. |
Sung JJ, Kim SJ, Lee HB. Anticholinesterase induces nicotinic receptor modulation.
Muscle Nerve. 1998;21:1135-44. |
8. |
Tune LE, Damlouji NF, Holland A. Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet. 1981;2(8248):651-3. |
|
9. |
Ludomirsky A, Klein HO, Sarelli P. Q-T prolongation and polymorphous (?torsade de pointes?) ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol. 1982;49:1654-8.
|
|
10.. |
Ben Abraham R, Weinbroum A. Resuscitative challenges in nerve agent poisoning.
Eur J Emerg Med. 2003;10:169-75. |
|
11. |
Lotti M, Becker CE, Aminoff MJ. Organophosphate polyneuropathy: pathogenesis
and prevention. Neurology. 1984;34:658-62. |
|
12. |
Trojan DA, Collet JP, Shapiro S. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology. 1999;53:1225-33. |
|
13. |
Singh G, Sidhu UP, Mahajan R. Phrenic nerve conduction studies in acute
organophosphate poisoning. Muscle Nerve.
2000;23:627-32. |
|
14. |
Savage EP, Keefe TJ, Mounce LM. Chronic neurological sequelae of acute organophosphate pesticide poisoning. Arch Environ Health. 1988;43:38-45. |
|
15. |
Rutchik JS, Rutkove SB: Effect of temperature on motor responses in organophosphate intoxication. Muscle Nerve. 1998;21:958-60. |
|
16. |
Chuang CC, Lin TS, Tsai MC. Delayed Neuropathy and Myelopathy after Organophosphate Intoxication. N Engl J Med. 2002;347:1119-21. |
|
17. |
Rosenstock L, Keifer M, Daniell WE: Chronic central nervous system effects of
acute organophosphate pesticide intoxication. The Pesticide Health Effects
Study Group. Lancet. 1991;338:223-7. |
|
18. |
Tafur AJ, Gonzalez L, Idrovo LA, Tafur
A. Unusual complication of an organophosphate poisoning. Emergency Medicine Journal. 2005;22:531. |
|
19. |
Rusyniak DE, Nanagas KA. Organophosphate Poisoning. Seminars in Neurology. Disorders of Neuromuscular Transmission. 2004;24:197-204. |
|
20. |
Teke E, Sungurtekin H, Sahiner T, Atalay H, Gur S. Organophosphate poisoning case with atypical clinical survey and magnetic resonance imaging findings. J Neurol
Neurosurg & Psy. 2004;75:936-7. |
|
21. |
Abou-Donia MB, Lapadula DM. Mechanisms of organophosphorus ester-induced delayed neurotoxicity: type I and type II. Ann Rev Pharmacol Toxicol. 1990;30:405-40. |
|
22. |
Funk KA, Henderson JD, Liu CH, Higgins RJ, Wilson BW. Neuropathology of
organophosphate-induced delayed neuropathy (OPIDN) in young chicks. Arch Toxicol.
1994;68:308-16. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|